Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-Mediated drug resistance

Biomaterials

Volumn 35, Issue 4, 2014, Pages 1227-1239

  Zeng, Xianghui ^a   Morgenstern, Ralf ^a   Nyström, Andreas M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Doxorubicin; Drug delivery; Drug resistance; Endocytosis; Glutathione transferase; Polymeric nanoparticle

Indexed keywords

DOXORUBICIN; DRUG RESISTANCE; ENDOCYTOSIS; GLUTATHIONE TRANSFERASE; POLYMERIC NANOPARTICLES;

CELL MEMBRANES; DRUG DELIVERY; MACHINERY; MILITARY VEHICLES; MOLECULAR BIOLOGY; NANOPARTICLES; PATIENT TREATMENT; PEPTIDES; POLYMERS;

CELL DEATH;

DOXORUBICIN; GLUTATHIONE TRANSFERASE; HYPERBRANCED DENDRITIC LINEAR BASED NANOPARTICLE; MICROSOMAL GLUTATHIONE TRANSFERASE 1; NANOPARTICLE; POLYESTER; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL MEMBRANE TRANSPORT; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SENSITIZATION; DRUG TRANSPORT; DRUG UPTAKE; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; LYSOSOME; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

C-JUN N-TERMINAL KINASE; DOX; DOX-HBDL; DOXORUBICIN; DRUG DELIVERY; DRUG RESISTANCE; ENDOCYTOSIS; GLUTATHIONE TRANSFERASE; HYPERBRANCHED DENDRITIC-LINEAR MICELLES ENCAPSULATING DOXORUBICIN; JNK; MGST1; MICROSOMAL GLUTATHIONE TRANSFERASE 1; POLYMERIC NANOPARTICLE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; FEMALE; GLUTATHIONE TRANSFERASE; HUMANS; NANOPARTICLES; SIGNAL TRANSDUCTION;

EID: 84888428832     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.10.042     Document Type: Article

References (55)

1. Bergh J., Jonsson P.E., Glimelius B., Nygren P., Grp S. Asystematic overview of chemotherapy effects in breast cancer. Acta Oncol 2001, 40:253-281.
2. Gottesman M.M., Pastan I. Biochemistry of multidrug-resistance mediated by the multidrug transporter. Annu Rev Biochem 1993, 62:385-427.
3. Boehm T., Folkman J., Browder T., OReilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997, 390:404-407.
4. Litman T., Druley T.E., Stein W.D., Bates S.E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001, 58:931-959.
5. Gao Z.B., Zhang L.N., Sun Y.J. Nanotechnology applied to overcome tumor drug resistance. JControl Release 2012, 162:45-55.
6. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5:219-234.
7. Zaman G.J.R., Lankelma J., Vantellingen O., Beijnen J., Dekker H., Paulusma C., et al. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci U S A 1995, 92:7690-7694.
8. Hayes J.D., Pulford D.J. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol 1995, 30:445-600.
9. Sau A., Tregno F.P., Valentino F., Federici G., Caccuri A.M. Glutathione transferases and development of new principles to overcome drug resistance. Arch Biochem Biophys 2010, 500:116-122.
10. Jabr-Milane L.S., van Vlerken L.E., Yadav S., Amiji M.M. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev 2008, 34:592-602.
11. Chow E.K., Zhang X.Q., Chen M., Lam R., Robinson E., Huang H.J., et al. Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment. Sci Transl Med 2011, 3:1-11.
12. Thierry A.R., Vige D., Coughlin S.S., Belli J.A., Dritschilo A., Rahman A. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. Faseb J 1993, 7:572-579.
13. Rahman A., Husain S.R., Siddiqui J., Verma M., Agresti M., Center M., et al. Liposome-mediated modulation of multidrug resistance in human Hl-60 leukemia-cells. JNatl Cancer Inst 1992, 84:1909-1915.
14. Stuart D.D., Kao G.Y., Allen T.M. Anovel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1. Cancer Gene Ther 2000, 7:466-475.
15. Nobili S., Landini I., Giglioni B., Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 2006, 7:861-879.
16. Greco F., Vicent M.J. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev 2009, 61:1203-1213.
17. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006, 6:688-701.
18. Kabanov A.V., Batrakova E.V., Alakhov V.Y. Pluronic((R)) block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 2002, 54:759-779.
19. Venne A., Li S.M., Mandeville R., Kabanov A., Alakhov V. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res 1996, 56:3626-3629.
20. Alakhov V.Y., Moskaleva E.Y., Batrakova E.V., Kabanov A.V. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug Chem 1996, 7:209-216.
21. Batrakova E.V., Li S., Elmquist W.F., Miller D.W., Alakhov V.Y., Kabanov A.V. Mechanism of sensitization of MDR cancer cells by pluronic block copolymers: selective energy depletion. Br J Cancer 2001, 85:1987-1997.
22. Chavanpatil M.D., Patil Y., Panyam J. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int J Pharm 2006, 320:150-156.
23. Minko T., Kopeckova P., Pozharov V., Kopecek J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. JControl Release 1998, 54:223-233.
24. Kievit F.M., Wang F.Y., Fang C., Mok H., Wang K., Silber J.R., et al. Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer invitro. JControl Release 2011, 152:76-83.
25. Lee C.C., MacKay J.A., Frechet J.M.J., Szoka F.C. Designing dendrimers for biological applications. Nat Biotechnol 2005, 23:1517-1526.
26. Svenson S., Tomalia D.A. Commentary - dendrimers in biomedical applications - reflections on the field. Adv Drug Deliv Rev 2005, 57:2106-2129.
27. Boas U., Heegaard P.M.H. Dendrimers in drug research. Chem Soc Rev 2004, 33:43-63.
28. Stiriba S.E., Frey H., Haag R. Dendritic polymers in biomedical applications: from potential to clinical use in diagnostics and therapy. Angew Chem Int Edit 2002, 41:1329-1334.
29. Morgan M.T., Nakanishi Y., Kroll D.J., Griset A.P., Carnahan M.A., Wathier M., et al. Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity invitro. Cancer Res 2006, 66:11913-11921.
30. Prabaharan M., Grailer J.J., Pilla S., Steeber D.A., Gong S.Q. Folate-conjugated amphiphilic hyperbranched block copolymers based on Boltorn (R) H40, poly(L-lactide) and poly(ethylene glycol) for tumor-targeted drug delivery. Biomaterials 2009, 30:3009-3019.
31. Xiao Y.L., Hong H., Javadi A., Engle J.W., Xu W.J., Yang Y.A., et al. Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials 2012, 33:3071-3082.
32. Lee C.C., Gillies E.R., Fox M.E., Guillaudeu S.J., Frechet J.M.J., Dy E.E., et al. Asingle dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc Natl Acad Sci U S A 2006, 103:16649-16654.
33. Gillies E.R., Dy E., Frechet J.M.J., Szoka F.C. Biological evaluation of polyester dendrimer: poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture. Mol Pharmaceut 2005, 2:129-138.
34. Gillies E.R., Frechet J.M.J. Designing macromolecules for therapeutic applications: polyester dendrimer-poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture. JAm Chem Soc 2002, 124:14137-14146.
35. Feliu N., Walter M.V., Montanez M.I., Kunzmann A., Hult A., Nystrom A., et al. Stability and biocompatibility of a library of polyester dendrimers in comparison to polyamidoamine dendrimers. Biomaterials 2012, 33:1970-1981.
36. Zeng X.H., Zhang Y.N., Nystrom A.M. Endocytic uptake and intracellular trafficking of bis-MPA-based hyperbranched copolymer micelles in breast cancer cells. Biomacromolecules 2012, 13:3814-3822.
37. Zeng X.H., Zhang Y.N., Wu Z.H., Lundberg P., Malkoch M., Nystrom A.M. Hyperbranched copolymer micelles as delivery vehicles of doxorubicin in breast cancer cells. JPolym Sci Pol Chem 2012, 50:280-288.
38. Morgenstern R., Zhang J., Johansson K. Microsomal glutathione transferase 1: mechanism and functional roles. Drug Metab Rev 2011, 43:300-306.
39. Johansson K., Ahlen K., Rinaldi R., Sahlander K., Siritantikorn A., Morgenstern R. Microsomal glutathione transferase 1 in anticancer drug resistance. Carcinogenesis 2007, 28:465-470.
40. Shi J.W., Karlsson H.L., Johansson K., Gogvadze V., Xiao L.S., Li J.T., et al. Microsomal glutathione transferase 1 protects against toxicity induced by silica nanoparticles but not by zinc oxide nanoparticles. Acs Nano 2012, 6:1925-1938.
41. Sahay G., Alakhova D.Y., Kabanov A.V. Endocytosis of nanomedicines. JControl Release 2010, 145:182-195.
42. Oberdorster G., Oberdorster E., Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Persp 2005, 113:823-839.
43. Gratton S.E.A., Ropp P.A., Pohlhaus P.D., Luft J.C., Madden V.J., Napier M.E., et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A 2008, 105:11613-11618.
44. Panyam J., Zhou W.Z., Prabha S., Sahoo S.K., Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. Faseb J 2002, 16:1217-1226.
45. Conner S.D., Schmid S.L. Regulated portals of entry into the cell. Nature 2003, 6(422):37-44.
46. Yeung B.G., Payne G.S. Clathrin interactions with C-terminal regions of the yeast AP-1 beta and gamma subunits are important for AP-1 association with clathrin coats. Traffic 2001, 2:565-576.
47. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9:615-627.
48. Morgenstern R., Lundqvist G., Andersson G., Balk L., Depierre J.W. The distribution of microsomal glutathione transferase among different organelles, different organs, and different organisms. Biochem Pharmacol 1984, 33:3609-3614.
49. Ang W.H., Khalaila I., Allardyce C.S., Juillerat-Jeanneret L., Dyson P.J. Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance. JAm Chem Soc 2005, 127:1382-1383.
50. Goto S., Iida T., Cho S., Oka M., Kohno S., Kondo T. Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. Free Radic Res 1999, 31:549-558.
51. Kroemer G., Galluzzi L., Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007, 87:99-163.
52. Vandenabeele P., Galluzzi L., Vanden Berghe T., Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010, 11:700-714.
53. Johansson K., Jarvliden J., Gogvadze V., Morgenstern R. Multiple roles of microsomal glutathione transferase 1 in cellular protection a mechanistic study. Free Radic Bio Med 2010, 49:1638-1645.
54. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell 2000, 13(103):239-252.
55. Tew K.D. Redox in redux: emergent roles for glutathione S-transferase P (GSTP) in regulation of cell signaling and S-glutathionylation. Biochem Pharmacol 2007, 73:1257-1269.